https://european-biotechnology.com/wp-content/uploads/2024/04/TargetED_Biopharmaceuticals-scaled.jpeg16302560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-22 16:34:312024-04-04 16:47:36TargED Biopharmaceuticals BV raises €39m in Series A financing
The cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
https://european-biotechnology.com/wp-content/uploads/2024/04/Lonza.jpeg571700Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-21 17:03:002024-04-04 16:47:44Moderna wants to extent its European footprint
InDex Pharmaceuticals needs a new COO. After ten years as Chief Operating Officer, Pernilla Sandwall will leave the Stockolm-based company at the end of April.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Pernilla_Sandwall_kl.jpg489435Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-02-17 11:24:002024-07-16 17:58:29COO will leave InDex Pharmaceuticals
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Newton_Capital.jpeg10002267Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-15 08:26:202024-04-04 16:47:46Newton Biocapital launches new NBC III fund
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_piggy-bank-g0355543d7_1280-pixabay.jpeg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-13 17:11:002024-04-04 16:47:47New funds to boost European life sciences
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
Laurence Riot Lamotte has started at the beginning of 2022 als new Chief Financial Officer of French Diaccurate. She succeeds José Da Gloria, who left the company.
TargED Biopharmaceuticals BV raises €39m in Series A financing
Latest NewsTargED Biopharmaceuticals will use €39m from a Series A financing to bring its thrombolytic treatment to patients.
Finnish VTT spin-out Onego Bio Ltd raises €10m
Latest NewsThe cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
Moderna wants to extent its European footprint
Latest NewsThe former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
COO will leave InDex Pharmaceuticals
AppointmentsInDex Pharmaceuticals needs a new COO. After ten years as Chief Operating Officer, Pernilla Sandwall will leave the Stockolm-based company at the end of April.
Centauri Therapeutics starting with £24m financing
Latest NewsAntimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics in US$1.7bn deal with MSD
Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital launches new NBC III fund
Latest NewsNewton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
New funds to boost European life sciences
Latest NewsEuropean investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
Latest NewsAiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
Solid financial experience for Diaccurate
AppointmentsLaurence Riot Lamotte has started at the beginning of 2022 als new Chief Financial Officer of French Diaccurate. She succeeds José Da Gloria, who left the company.